vs
Side-by-side financial comparison of Currenc Group Inc. (CURR) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
Currenc Group Inc. is the larger business by last-quarter revenue ($10.1M vs $9.3M, roughly 1.1× STRATA Skin Sciences, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -46.5%, a 47.1% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -23.3%). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-1.7M).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
CURR vs SSKN — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.1M | $9.3M |
| Net Profit | $-4.7M | $58.0K |
| Gross Margin | 31.8% | 61.8% |
| Operating Margin | -43.0% | 5.3% |
| Net Margin | -46.5% | 0.6% |
| Revenue YoY | -23.3% | -3.0% |
| Net Profit YoY | -54.0% | 101.3% |
| EPS (diluted) | $-0.13 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $9.3M | ||
| Q3 25 | — | $6.9M | ||
| Q2 25 | — | $7.7M | ||
| Q1 25 | $10.1M | $6.8M | ||
| Q4 24 | — | $9.6M | ||
| Q3 24 | $11.3M | $8.8M | ||
| Q2 24 | — | $8.4M | ||
| Q1 24 | $13.1M | $6.8M |
| Q4 25 | — | $58.0K | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | $-2.6M | ||
| Q1 25 | $-4.7M | $-2.1M | ||
| Q4 24 | — | $-4.6M | ||
| Q3 24 | $-5.0M | $-2.1M | ||
| Q2 24 | — | $-91.0K | ||
| Q1 24 | $-3.0M | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | 31.8% | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | 27.8% | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | 33.6% | 45.6% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | -16.9% | ||
| Q2 25 | — | -30.1% | ||
| Q1 25 | -43.0% | -25.0% | ||
| Q4 24 | — | -44.7% | ||
| Q3 24 | -141.5% | -18.2% | ||
| Q2 24 | — | -5.7% | ||
| Q1 24 | -10.8% | -42.7% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | -23.4% | ||
| Q2 25 | — | -33.6% | ||
| Q1 25 | -46.5% | -31.2% | ||
| Q4 24 | — | -47.6% | ||
| Q3 24 | -44.1% | -23.6% | ||
| Q2 24 | — | -1.1% | ||
| Q1 24 | -23.2% | -49.8% |
| Q4 25 | — | $0.14 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $-0.62 | ||
| Q1 25 | $-0.13 | $-0.51 | ||
| Q4 24 | — | $-2.01 | ||
| Q3 24 | $-0.13 | $-0.51 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | $-0.09 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $62.3M | $7.9M |
| Total DebtLower is stronger | $3.7M | $15.3M |
| Stockholders' EquityBook value | $-68.4M | $2.9M |
| Total Assets | $110.8M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.9M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | $62.3M | $6.5M | ||
| Q4 24 | — | $7.3M | ||
| Q3 24 | $49.1M | $7.1M | ||
| Q2 24 | — | $5.5M | ||
| Q1 24 | — | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | $3.7M | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | $20.1M | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $1.3M | ||
| Q2 25 | — | $532.0K | ||
| Q1 25 | $-68.4M | $3.0M | ||
| Q4 24 | — | $5.0M | ||
| Q3 24 | $-47.0M | $9.4M | ||
| Q2 24 | — | $9.5M | ||
| Q1 24 | $-10.9M | $9.4M |
| Q4 25 | — | $30.5M | ||
| Q3 25 | — | $30.7M | ||
| Q2 25 | — | $29.5M | ||
| Q1 25 | $110.8M | $33.0M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $115.0M | $39.4M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | $54.5M | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.5M | $-239.0K |
| Free Cash FlowOCF − Capex | $-1.7M | $-551.0K |
| FCF MarginFCF / Revenue | -16.5% | -5.9% |
| Capex IntensityCapex / Revenue | 1.7% | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-239.0K | ||
| Q3 25 | — | $-64.0K | ||
| Q2 25 | — | $-1.9M | ||
| Q1 25 | $-1.5M | $-550.0K | ||
| Q4 24 | — | $703.0K | ||
| Q3 24 | $-11.3M | $-302.0K | ||
| Q2 24 | — | $591.0K | ||
| Q1 24 | $-221.0K | $-804.0K |
| Q4 25 | — | $-551.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | $-1.7M | $-749.0K | ||
| Q4 24 | — | $199.0K | ||
| Q3 24 | — | $-364.0K | ||
| Q2 24 | — | $246.0K | ||
| Q1 24 | $-233.0K | $-1.5M |
| Q4 25 | — | -5.9% | ||
| Q3 25 | — | -15.6% | ||
| Q2 25 | — | -26.1% | ||
| Q1 25 | -16.5% | -11.0% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | -4.1% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | -1.8% | -22.6% |
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | 1.7% | 2.9% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 4.1% | ||
| Q1 24 | 0.1% | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CURR
| Sales Of Airtime | $5.5M | 54% |
| Fiat Remittance Service | $4.4M | 44% |
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
